Pulmonx to Present at the Bank of America Securities 2025 Health Care Conference
Pulmonx Corporation (NASDAQ: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the upcoming Bank of America Securities 2025 Health Care Conference. The presentation is scheduled for Wednesday, May 14, 2025, at 9:35 AM PT / 12:35 PM ET in Las Vegas. Investors and interested parties can access both the live and archived webcast of the presentation through the company's investor relations website at investors.pulmonx.com.
Pulmonx Corporation (NASDAQ: LUNG), azienda leader nei trattamenti minimamente invasivi per le malattie polmonari gravi, ha annunciato la sua partecipazione alla prossima Bank of America Securities 2025 Health Care Conference. La presentazione è prevista per mercoledì 14 maggio 2025, alle 9:35 AM PT / 12:35 PM ET a Las Vegas. Investitori e interessati potranno seguire la diretta e rivedere la registrazione della presentazione tramite il sito web delle relazioni con gli investitori della società, all'indirizzo investors.pulmonx.com.
Pulmonx Corporation (NASDAQ: LUNG), líder en tratamientos mínimamente invasivos para enfermedades pulmonares graves, ha anunciado su participación en la próxima Bank of America Securities 2025 Health Care Conference. La presentación está programada para el miércoles 14 de mayo de 2025, a las 9:35 AM PT / 12:35 PM ET en Las Vegas. Los inversores y partes interesadas podrán acceder a la transmisión en vivo y a la grabación de la presentación a través del sitio web de relaciones con inversores de la compañía en investors.pulmonx.com.
Pulmonx Corporation (NASDAQ: LUNG)는 중증 폐 질환에 대한 최소 침습 치료의 선두주자로서 다가오는 Bank of America Securities 2025 Health Care Conference에 참여한다고 발표했습니다. 발표는 2025년 5월 14일 수요일 오전 9:35 PT / 오후 12:35 ET 라스베이거스에서 예정되어 있습니다. 투자자와 관심 있는 분들은 회사의 투자자 관계 웹사이트 investors.pulmonx.com을 통해 생중계 및 녹화된 웹캐스트를 시청할 수 있습니다.
Pulmonx Corporation (NASDAQ : LUNG), leader dans les traitements peu invasifs des maladies pulmonaires sévères, a annoncé sa participation à la prochaine Bank of America Securities 2025 Health Care Conference. La présentation est prévue pour le mercredi 14 mai 2025 à 9h35 PT / 12h35 ET à Las Vegas. Les investisseurs et parties intéressées pourront accéder à la diffusion en direct ainsi qu'à la rediffusion de la présentation via le site web des relations investisseurs de la société à l'adresse investors.pulmonx.com.
Pulmonx Corporation (NASDAQ: LUNG), ein führendes Unternehmen für minimalinvasive Behandlungen schwerer Lungenerkrankungen, hat seine Teilnahme an der bevorstehenden Bank of America Securities 2025 Health Care Conference angekündigt. Die Präsentation findet am Mittwoch, den 14. Mai 2025, um 9:35 Uhr PT / 12:35 Uhr ET in Las Vegas statt. Investoren und Interessierte können die Live-Übertragung sowie die Aufzeichnung der Präsentation über die Investor-Relations-Website des Unternehmens unter investors.pulmonx.com verfolgen.
- None.
- None.
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Wednesday, May 14, 2025, at 9:35 AM PT / 12:35 PM ET.
A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Contact
Brian Johnston
Laine Morgan
Gilmartin Group
investors@pulmonx.com
FAQ
When is Pulmonx (LUNG) presenting at the Bank of America Securities Healthcare Conference 2025?
How can I watch Pulmonx's (LUNG) presentation at the BofA Healthcare Conference?
What does Pulmonx Corporation (LUNG) specialize in?
Where is the Bank of America Securities 2025 Health Care Conference being held?
